Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in combination with Genprex’s (NASDAQ: GNPX) gene therapy, Reqorsa (quaratusugene ozeplasmid), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Genprex has initiated the dose escalation phase of a Phase I clinical trial, with the company anticipating completion in the second half of 2024.
Reqorsa is engineered to express the tumor suppressor gene protein TUSC2, which is often downregulated or absent in SCLC tumors, making it a promising therapeutic target.- Flcube.com
